Equities research analysts expect KemPharm (NASDAQ:KMPH) to report earnings per share of ($0.70) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for KemPharm’s earnings. The highest EPS estimate is ($0.68) and the lowest is ($0.72). KemPharm reported earnings of ($0.84) per share during the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The business is scheduled to issue its next earnings report on Wednesday, May 9th.
On average, analysts expect that KemPharm will report full-year earnings of ($2.59) per share for the current financial year, with EPS estimates ranging from ($2.60) to ($2.57). For the next year, analysts anticipate that the business will report earnings of ($2.48) per share, with EPS estimates ranging from ($3.09) to ($2.00). Zacks’ EPS calculations are an average based on a survey of analysts that cover KemPharm.
KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.04).
Several brokerages recently weighed in on KMPH. Zacks Investment Research downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Thursday, March 22nd. Oppenheimer reiterated a “buy” rating on shares of KemPharm in a research report on Thursday, March 22nd. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Friday, March 9th. Finally, Roth Capital set a $10.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research report on Monday, April 2nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. KemPharm currently has a consensus rating of “Buy” and a consensus target price of $10.05.
An institutional investor recently raised its position in KemPharm stock. Victory Capital Management Inc. grew its stake in shares of KemPharm (NASDAQ:KMPH) by 26.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,077 shares of the specialty pharmaceutical company’s stock after buying an additional 34,114 shares during the quarter. Victory Capital Management Inc. owned about 1.11% of KemPharm worth $656,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 35.47% of the company’s stock.
NASDAQ:KMPH traded up $0.10 during mid-day trading on Monday, hitting $6.60. The stock had a trading volume of 55,869 shares, compared to its average volume of 167,926. The company has a market cap of $98.18, a PE ratio of -2.23 and a beta of -0.36. KemPharm has a 52 week low of $2.45 and a 52 week high of $8.40. The company has a quick ratio of 4.09, a current ratio of 4.09 and a debt-to-equity ratio of -1.56.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/16/0-70-eps-expected-for-kempharm-kmph-this-quarter.html.
KemPharm Company Profile
KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.
Get a free copy of the Zacks research report on KemPharm (KMPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.